🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "major milestone" in the fight against superbug strains of the bacteria, according to scientists.

A Global Challenge

Cases of gonorrhoea are on the rise around the world, with estimates suggesting more than 82 million instances each year. Especially elevated rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have hit a record high, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely development in the reality of increasing worldwide cases, escalating drug resistance and the highly restricted available drugs presently on offer.”

Medical experts are deeply concerned about the increase in drug-resistant strains. The World Health Organization has designated it as a "critical concern". Recent surveillance revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Treatment Options Receive Authorization

Zoliflodacin, also known as a brand name, was approved by the US Food and Drug Administration in mid-December for use against gonorrhoea. This STI can lead to major issues, including infertility. Experts hope that specific application of this new drug will help slow the development of resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, also received approval in the same week. This treatment, which is also used to treat urinary tract infections, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

This new treatment stemmed from a new, not-for-profit approach for drug creation. The charitable organization GARDP partnered with the pharmaceutical company its industry partner to develop it.

“This authorization signifies a major breakthrough in the management of multidrug-resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Research Study Outcomes and Global Access

According to findings detailed in a prominent scientific publication, zoliflodacin eradicated more than 90% of uncomplicated infections. This establishes an comparable level with the current standard treatment, which involves an injection and a pill. The research enrolled nearly 1,000 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the authority to make available and distribute the drug in a wide range of low-income and middle-income countries.

Medical professionals treating patients have expressed optimism. The availability of a easy-to-administer therapy such as this is seen as a "critical tool" for public health efforts. This is viewed as vital to alleviate the strain of the illness for individuals and to prevent the spread of highly drug-resistant gonorrhoea worldwide.